RIO DE JANEIRO, BRAZIL - The National Health Regulatory Agency (ANVISA) on Friday, October 23rd, authorized the import of six million doses of CoronaVac, the Chinese vaccine that should be produced by the Butantan Institute, in São Paulo.
The decision does not address the request made by the São Paulo government to authorize the import of the necessary raw materials for the production of another 40 million doses in Brazil.
CoronaVac is currently in its third trial phase. Sinovac, the Chinese pharmaceutical company responsible for the vaccine, has not yet been granted registration to administer the immunizer, which cannot . . .